key: cord-0754984-t9ihpvyd
authors: Chodick, Gabriel; Tene, Lilac; Rotem, Ran S; Patalon, Tal; Gazit, Sivan; Ben-Tov, Amir; Weil, Clara; Goldshtein, Inbal; Twig, Gilad; Cohen, Dani; Muhsen, Khitam
title: The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data
date: 2021-05-17
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab438
sha: 952c6ae7e915c94e74ed4cf1d0b682f0a83fa85a
doc_id: 754984
cord_uid: t9ihpvyd

BACKGROUND: COVID-19 mRNA vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality. METHODS: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least one dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with rt-PCR, between 7 to 27 days after second dose (protection-period), as compared to days 1 to 7 after the first dose, where no protection by the vaccine is assumed (reference-period). RESULTS: Data of 1,178,597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD=18.1], 48.4% males) of whom 872,454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100,000 (95%CI: 26.1-115.0 per 100,000) and 5.4 per 100,000 (95%CI: 3.5-8.4 per 100,000), respectively. The vaccine effectiveness in preventing infection was 90% (95%CI:79%- 95%) and 94% (95%CI:88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95%CI:37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95%CI:0.36-1.88), 0.45 (95%CI:0.23-0.90), and 0.56 (95%CI:0.36-0.89) in the age groups 16-44, 45-64 and 75 and above, respectively. CONCLUSIONS: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.

The recently authorized BNT162b2 mRNA COVID-19 vaccine has demonstrated 95% efficacy in preventing COVID-19 with the two-dose regimen in phase III placebo-controlled randomized clinical trial (RCT). 1 Observational studies using real-world data are important for providing a robust assessment and external validity on vaccine safety and effectiveness in the general population and across diverse populations, including in those that are often excluded from the RCTs such as patients with unstable comorbid conditions. 1,2 Additionally, large observational studies using real world data with longer follow-up time may allow the assessment of low-probability effects that may not be detected in RCTs.

In Israel, COVID-19 vaccination using BNT162b2 mRNA vaccine started on December 19, 2020, with priority given initially to individuals aged 60 and above, healthcare workers and high-risk groups with chronic conditions. By comparing vaccinated with unvaccinated Israelis, a recent real-world data analysis 3,4 estimated the vaccine effectiveness (VE) of two doses of BNT162b2 in reducing COVID-19 risk at 91%. Comparisons of vaccinated and unvaccinated individuals might be challenging given inherited unmeasured characteristics that may differ between the groups such as perceived infection risk, poorer compliance with COVID-19 preventive measure which might result in biases. 5 This challenge is amplified when vaccine uptake is rapid. We propose an alternative design that overcomes this pitfall with a cohort study of vaccinated individuals only comparing the incidence of the infection during the first few days after immunization with first vaccine dose to at-least one-week post second dose. This design allows a valid estimation of the VE given that COVID-19 incidence was similar in the vaccine and placebo arms during the first week after immunization in the RCT. 6 As of February 25 2021, Israel ranks first in vaccine coverage with 75% of the individuals aged 16 or above vaccinated with at least one dose of BNT162b2 vaccine. The aim of the A c c e p t e d M a n u s c r i p t current study was to expand our previous research on first dose 7 and assess the effectiveness of two-dose BNT162b2 vaccine in reducing the risk of SARS-CoV-2 infection in a large cohort of immunized individuals, employing a vaccine-only study design.

The data used for this retrospective cohort study were obtained from Maccabi Healthcare Services (MHS), a state-mandated sick fund, covering 2.6 million-member or 25% of residents in Israel. According to the National Health Insurance Law, membership in sick funds is free and open to all Israeli citizens. MHS database includes extensive demographic data, anthropometric measurements, diagnoses from community clinics and hospitals, medication dispensing information, and comprehensive laboratory data from a single central laboratory.

The study population consisted of all MHS members aged 16 and above who were vaccinated with at least one dose of the BNT162b2 vaccine during a mass immunization program from December 19, 2020 to February 20, 2021. Excluded from analysis were patients who had a documented positive SARS-CoV-2 prior to vaccination date (n=13,656) and individuals who joined MHS after February 2020 and therefore had an incomplete medical history (n=33,666).

The results of the phase III trial 6 provide experimental evidence that the BNT162b2 vaccine confreres no or little protection against SARS-CoV-2 infection during the first seven days post vaccination with the first dose. This is also supported by a recent analysis of the infection cycle threshold (Ct) over time among infected vaccinees in MHS, where viral load substantially decreased only after 12 days after first dose 8 . Therefore, we used the incidence A c c e p t e d M a n u s c r i p t of infection in day 1 to 7 after first dose as a reference period to assess the effectiveness of the vaccine compared to days 7 to 72 after the second dose, which was defined as the protection period based on the phase III trial data 1 . We limit to 27 days to allow sufficient time for post infection follow-up. 

Continuous variables were expressed as means (standards deviations [SD]) and medians (interquartile range, IQR). Categorical variables were summarized as counts and percentages.

Cumulative incidence plots of SARS-CoV-2 infection were created using Kaplan-Meier survival analysis and compared with the log-rank test. The comparison of the incidence rate of rt-PCR-confirmed SARS-CoV-2 infection between the two study periods was performed using generalized linear models, applying a negative-binomial distribution with a log-link and log-daily number of individuals-at-risk as an offset. The offset was used to scale the counts of SARS-CoV-2 infections to daily incidence, expressed as cases per 100,000. The dependent variable was the number of positive PCR per day during each study period. VE was defined as infection relative risk reduction and calculated as: (1relative risk) × 100. Analyses were stratified by age group, sex, patients residing in ultraorthodox Jewish or Israeli Arab sector, and chronic illness. We also stratified the analysis by calendar period to assess the potential effect of new SARS-CoV-2 variants that were spread during the study period (eFigure 1). 14 Binary logistic regression models were used to estimate odds ratios (ORs), adjusted odds ratios (aORs) and 95% CIs for COVID-19 symptoms among infected patients. All binary logistic regression models estimating the aORs simultaneously controlled for age, sex, sector, SES, and chronic conditions. Adjusted hazard ratios (aHRs) for COVID-19-related hospitalization or death among infected patients were calculated using Cox proportional hazards model adjusting for age, sex, calendar period of immunization, sector, and clinical characteristics. The corresponding adjusted survival curves were drawn. Proportional hazards assumption was confirmed according to Schoenfeld residuals tests and graphical evaluations.

To assess potential "healthy vaccinee" bias where incidence in the first days after first dose A c c e p t e d M a n u s c r i p t are lower than general population due to selection of COVID-19-free patients, we performed a sensitivity analysis limiting the reference-period to days 5 to 7 after first dose (N=1,175,741). Analyses were done using IBM-SPSS Version 27 (Armonk, NY: IBM Corp) and R packages magrittr, readtext, dplyr, ggplot2, tidyverse, survival, forestplot, and survminer.

The study protocol was approved by the MHS Ethics Committee. between reference period and protection period was found across all age groups (Figure 1 ).

The overall VE was estimated at 90% (95% CI: 79%-95%), which was materially unchanged when limiting reference-period to days 5 to 7 after first dose, VE against infection was 92% (95%CI, 75%-97%) (Supplementary Table 1 

A c c e p t e d M a n u s c r i p t VE estimates were 92% (95% CI: 83%-96%) and 90% (95% CI: 80%-95%) in the age groups 16-44 and 45-64 years respectively, 82% (95% CI: 63%-92%) in the age groups 65-74 and 82% in those aged 75 and above (95% CI: 61%-91%). In patients with diabetes and patients with cardiovascular diseases, the estimated VE was 82% (95%CI: 62% to 92%). Somewhat lower VE (71%; 95%CI: 37%-87%) was calculated among immunosuppressed patients, approaching 52% (95%CI: -26% to 82%) in those who were 65 and older ( Figure 2 ). In stratified analysis among immunosuppressed patients during the first month of the vaccination campaign, VE was 70% (95%CI: 35% to 86%) compared to 84% (60%-94%) in the second month (Supplementary Table 2 ). The overall estimated VE in preventing COVID-19 was 94% (95%CI: 87%-97%), and 75% (95% CI: 44%-88%) among immunosuppressed patients ( Figure 2 ). To our knowledge, this is the largest cohort of vaccinated persons that assessed VE. With this sizable sample and 728 incident PCR-confirmed SARS-CoV-2 infections starting at 7 days after second dose, we were able to estimate VE among different subpopulations. VE in patients with underlying chronic conditions including diabetes, hypertension, cardiovascular diseases or cancer was somewhat lower (approximately 82%) compared to the population average of 90%. In a previous observational study from a large health provider in Israel 3 , VE in persons with diabetes or hypertension was similar to the general population, although patients with over three major chronic morbidities had diminished effectiveness. A more substantial difference was found among immunosuppressed patients who had an average VE of 70%, which was further reduced among the elderly. Current data on the risk of COVID-19 morbidity patients with immunosuppression are limited 17 as these patients more strongly adhere to exposure-limiting precautions compared to the general population. Thus, more A c c e p t e d M a n u s c r i p t research is required to characterize the immunologic profile of these groups to ensure optimal protection. 18 In addition to estimating VE, our analysis evaluated the potential benefit of the vaccine in reducing the risk of COVID-19 hospitalizations and death among patients with vaccine failure in preventing infection. Individuals who were infected starting at day 7 after the second dose were substantially less likely to present symptoms and to be hospitalized compared to those who were infected in the reference period. A comparable reduction of 60% in hospital admissions after vaccination was observed in a previous observational study. 16 Similarly, our results indicate a lower case-fatality of COVID-19 cases infected during protection period compared to the reference period as was previously observed 3 . However, it can be argued that a hospitalization rate of 6.9% and case-fatality rate of 1.5% in those after the second dose are not negligible, especially not in patients with immunosuppression. It is therefore might be important to retain awareness among vaccinated patients and their caregivers to possible severe COVID-19 when breakthrough infection occurs.

Previous observational studies compared vaccinated and matched unvaccinated patients, which could introduce selection bias due to unmeasured confounders such as health literacy, perceived feelings of vulnerability to COVID-19, and differences in health seeking behavior. 5, 19 Moreover, these comparative studies are also susceptible to a healthy vaccine bias, as immunized individuals are more likely to feel well on the vaccination date while patients with symptoms or suspected contacts are discouraged from immunization. 20 Rigorous matching in these studies was employed to make the vaccinated and unvaccinated populations comparable, but is done at the cost of excluding many vaccinated individuals for whom a match cannot be found. For example, in the study by Dagan This study has some limitations. Although 74% of the study participants were included in both periods, follow-up distributed differently over calendar time. However, when analyses were stratified by calendar week, results remained materially unchanged. In addition, we assessed COVID-19 symptoms from physician reports at patient's visits. Thus, symptoms that developed after that visit were not captured in our data. Additional limitation is change in health seeking behavior between the periods where patients after two doses may have a lower test rate, leaving more asymptomatic infections undocumented. Nevertheless, this potential information bias is likely insignificant, as VE calculated for all infections was similar or lower to the one calculated for symptomatic cases. Finally, the "healthy vaccinee" effect should also be considered when using the incidence in the first days after first dose as a reference period, although sensitivity analysis suggested that the attenuation in the estimated VE is relatively small.

With more than 86% of adults in MHS are currently covered with at least one dose of BNT162B2, COVID-19 morbidity is still significant. Although the relative importance of children and young adolescents in SARS-CoV-2 transmission is still unclear, their vaccination seems to be essential to support herd immunity. This underlines the importance of several COVID-19 pediatric vaccines trials that are underway. 21 We report a high effectiveness of the BNT162b2 vaccine for preventing documented SARS-CoV-2 infection in real-world setting, corroborating estimates reported in previous randomized trial and observational analyses. Our study also suggests that second dose of the vaccine reduced, but not nullified, the risk of hospitalization among infected patients. The relationship between immunosuppression and BNT162b2 VE should be further explored.

A c c e p t e d M a n u s c r i p t Although this early evidence is highly encouraging, new challenges are imposed with the emergence of the new SARS CoV 2 variants. It is necessary therefore to reassess the effectiveness of the vaccine periodically in the general population and in various subpopulations.

There was no external funding for this analysis.

No author has a potential conflict of interest or funding source M a n u s c r i p t 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Looking beyond COVID-19 vaccine phase 3 trials

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet

Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health-Europe

FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine

The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Longitudinal symptom dynamics of COVID-19 infection

The epidemiology of diabetes in a large Israeli HMO

The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization

Effect of Socioeconomic and Ethnic Characteristics on COVID-19 Infection: the Case of the Ultra-Orthodox and the Arab Communities in Israel

European Centre for Disease Prevention and Control. Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA, first update -21

Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study

FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. medRxiv

Immunosuppression as a risk factor for COVID-19: a meta-analysis

COVID-19 vaccination in immunocompromised patients

Predictors of the intention to receive a SARS-CoV-2 vaccine

Influenza vaccination for all pregnant women? So far the less biased evidence does not favour it

Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t